Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.

Details

Ressource 1Download: BIB_407039255E66.P001.pdf (704.30 [Ko])
State: Public
Version: author
License: Not specified
Serval ID
serval:BIB_407039255E66
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.
Journal
Molecular Cancer
Author(s)
Roulin D., Waselle L., Dormond-Meuwly A., Dufour M., Demartines N., Dormond O.
ISSN
1476-4598 (Electronic)
ISSN-L
1476-4598
Publication state
Published
Issued date
2011
Peer-reviewed
Oui
Volume
10
Pages
-
Language
english
Notes
Publication types: Journal ArticlePublication Status: epublish
Abstract
Background: Targeted therapies for metastatic renal cell carcinoma (RCC), including mammalian target of rapamycin (mTOR) inhibitors and small-molecule multikinase inhibitors, have produced clinical effects. However, most patients acquire resistance over time. Thus, new therapeutic strategies need to be developed. Here, we evaluated the effect of the dual PI3K/mTOR inhibitor NVP-BEZ235, in combination with the multikinase inhibitor sorafenib on renal cancer cell proliferation and survival in vitro as well as on tumor growth in vivo.Methods: The renal carcinoma cell lines 786-0 and Caki-1 were treated with NVP-BEZ235 or sorafenib, either alone or in combination. Tumor cell proliferation and apoptosis were investigated in vitro. The anticancer efficacy of NVP-BEZ235 alone, or in combination with sorafenib, was also evaluated on RCC xenografts in nude mice.Results: Treatment of 786-0 and Caki-1 cells with NVP-BEZ235 or sorafenib resulted in reduced tumor cell proliferation and increased tumor cell apoptosis in vitro. The combination of NVP-BEZ235 and sorafenib was more effective than each compound alone. Similarly, in vivo, NVP-BEZ235 or sorafenib reduced the growth of xenografts generated from 786-0 or Caki-1 cells. The antitumor efficacy of NVP-BEZ235 in combination with sorafenib was superior to NVP-BEZ235 or sorafenib alone.Conclusions: Our findings indicate that the simultaneous use of NVP-BEZ235 and sorafenib has greater antitumor benefit compared to either drug alone and thus provides a treatment strategy in RCC.
Pubmed
Web of science
Open Access
Yes
Create date
09/09/2011 10:32
Last modification date
14/05/2020 6:23
Usage data